Diagnostics Q3 net loss narrows on lower expenses

Co-Diagnostics

13/11/2025 21:09

Overview

Co-Diagnostics Q3 revenue of $0.1 mln missed analyst expectations

Net loss for Q3 narrows to $5.9 mln from $9.7 mln in prior year

Operating expenses decreased 32.6% year-over-year to $7.1 mln

Result Drivers

REVENUE DECLINE - Co attributes revenue decrease to reduction in grant revenue compared to prior period

STRATEGIC INITIATIVES - CoMira JV in Saudi Arabia and AI business unit launched to drive future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$100,000
$150,000 (2 Analysts)
Q3 EPS
-$0.16
Q3 Net Income
-$5.90 mln
Q3 Adjusted EBITDA
-$6.30 mln
Q3 Operating Expenses
$7.10 mln
Q3 Operating Income
-$7 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Co-Diagnostics Inc is $2.00, about 80.2% above its November 12 closing price of $0.40

Press Release: ID:nPn1nnZ8la

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)